European Heart Journal Advance Access originally published online on May 19, 2005
European Heart Journal 2005 26(14):1448-1449; doi:10.1093/eurheartj/ehi319
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Recombinant streptokinase: evidences from clinical use
Institute for Cardiology and Cardiovascular Surgery
Calle 17 y A
Vedado
Havana, Cuba
Tel: +53 7 8307250
Fax: +53 7 8344435
E-mail address: dircardio@infomed.sld.cu
Institute for Cardiology and Cardiovascular Surgery
Calle 17 y A
Vedado
Havana, Cuba
Tel: +53 7 8307250
Fax: +53 7 8344435
Center for Biological Research
Clinical Trials Division
Havana, Cuba
| The first 10% of the full text of this article appears below. |
In the study of Hermentin et al.,1 a significant discrepancy between claimed and measured streptokinase (SK) activity of various tested products was found in addition to other physicochemical differences. However, it is difficult to interpret the results as they analysed